Month: March 2026

Commerce Split Corp. Announces Capital Share Split and Increased Distributions

Written by Customer Service on March 2, 2026. Posted in Dividend Reports And Estimates.

TORONTO, March 02, 2026 (GLOBE NEWSWIRE) — Commerce Split Corp. (the “Company”) is pleased to announce its intention to complete a share split of its Capital Shares (the “Share Split”) and to increase the targeted distributions payable on the Capital Shares, reflecting the strong performance of the Company. Capital shareholders of record at the close of business on March 6, 2026 will receive 10 additional Capital Shares for every 100 Capital Shares held, pursuant to the Share Split. The Share Split is subject to approval by the Toronto Stock Exchange (the “TSX”). In addition, the Company intends to increase the targeted monthly distribution on the Capital Shares to $0.075 per share ($0.90 annually) from $0.05 per share ($0.60 annually). After giving effect to the Share Split, this represents an approximate 65% increase in total...

AVAX One Reports Preliminary Full Year 2025 Financial Results & Introduces 2026 Guidance

Written by Customer Service on March 2, 2026. Posted in Public Companies.

WEST PALM BEACH, FL, March 02, 2026 (GLOBE NEWSWIRE) — AVAX One Technology Ltd. (Nasdaq: AVX) (“AVAX One” or the “Company”), today reported its preliminary financial results for the full year ended December 31, 2025, and introduced financial guidance for fiscal year 2026. Preliminary Full Year 2025 Financial Highlights ($ in Millions USD, unaudited) 9-Months Ended Sep’25 3-Months Ended Dec’251 12-Months Ended Dec’25Revenue $1.3M $1.1M $2.3MEBITDA2 $(5.2)M $(2.1)M $(7.3)M Full Year 2026 Guidance ($ in Millions USD) Current Spot Price3 2025 Avg. Price4 2025 High Price5Revenue $11M – $12M $24M – $25M $43M – $44MChange vs. prior year period ~5x ~10x ~19xEBITDA2 $2M – $3M $10M – $11M $24M – $25M The Company also preliminarily reports the following...

Monument Reports Second Quarter Fiscal 2026 Results

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Gross Revenue of US$49.23 Million and Cash Cost of US$1,288/Oz VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its financial results for the three months ended December 31, 2025 (“Q2 FY 2026”). All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). President and CEO Cathy Zhai commented, “In Q2 FY 2026, gold production and sales at the Selinsing Gold Mine in Malaysia, together with favourable gold prices, contributed to strong cash flow and enhanced the Company’s financial position. During the quarter, cash reserves increased by $19.81 million to $82.65 million, providing robust liquidity to support future growth initiatives. Exploration drilling at...

Colliers acquires Rome’s leading residential asset advisor

Written by Customer Service on March 2, 2026. Posted in Mergers And Acquisitions.

Enhances capabilities in development and urban regeneration projectsColliers acquires Progedil, Rome’s leading residential asset advisorColliers acquires Progedil, expanding Colliers’ ability to advise on large-scale urban regeneration and new-build development projects.ROME, March 02, 2026 (GLOBE NEWSWIRE) — Global diversified professional services and investment management company Colliers announces the acquisition of Progedil, expanding Colliers’ ability to advise on large-scale urban regeneration and new-build development projects in one of Italy’s most dynamic residential markets. As part of the transaction, Progedil’s senior leadership team has retained significant equity in the business and will continue to lead the day-to-day operations. Progedil provides full-service project marketing for residential...

BioSyent Announces Closing of the Acquisition of Oral Science Inc.

Written by Customer Service on March 2, 2026. Posted in Mergers And Acquisitions.

MISSISSAUGA, Ontario, March 02, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture (TSXV): RX) is pleased to announce that it has successfully closed the previously-announced acquisition of Oral Science Inc. (“Oral Science”), a privately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec. Pursuant to the terms of a Share Purchase Agreement (“SPA”) dated February 8, 2026, BioSyent, through its wholly-owned subsidiary, completed the acquisition of Oral Science from the shareholders of Oral Science (the “Sellers”) in an arm’s length transaction. The aggregate purchase price was $25.5 million, satisfied by: (i) a cash payment of $22.5 million to the Sellers of which $0.2 million will be satisfied with the grant of 12,666 Restricted Share Units (“RSUs”)...

Reminder to register: Invitation to Multitude AG’s FY2025 Preliminary Results Presentation – Join us virtually on 12 March 2026 at 10 am CET

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Zug, 02 March 2026 – Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized enterprises, and other FinTechs (WKN: A40VJN, ISIN: CH1398992755) (“Multitude”, “Company” or “Group”) warmly invites financial analysts, investors, and media to its FY2025 Preliminary Results Presentation webcast. The event will be held virtually on Thursday, 12 March 2026, at 10:00 am CET. A link for registration to the webcast is available on the company website in the subsection financial calendar https://www.multitude.com/investors/financial-calendar. Contact:Multitude AG Grafenauweg 8 6300 Zug Switzerland Adam Hansson TönningHead of IR and TreasuryPhone: +46733583171ir@multitude.com About Multitude AG: Multitude is a listed European FinTech company, offering digital lending...

Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline

Written by Customer Service on March 2, 2026. Posted in Mergers And Acquisitions.

Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust pipeline of degraders, targeting inflammatory diseases and cancers. Access to degrader-antibody conjugates (DACs) platform technology for future discovery engine. Strengthened leadership team designed to support future global growth. Transaction is anticipated to close early in the second quarter of 2026. An updated corporate presentation has been posted to the Gyre and Cullgen websites.SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced its agreement to acquire...

Bitcoin Depot Expands Product Portfolio with Acquisition of Social Betting Platform, Kutt

Written by Customer Service on March 2, 2026. Posted in Mergers And Acquisitions.

Company Enters Peer-to-Peer Social Betting Market as Part of Broader Product Diversification Strategy ATLANTA, March 02, 2026 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced that it has acquired Kutt, a peer-to-peer (“P2P”) social betting platform that enables users to wager directly against each other on both private and publicly verifiable events. The acquisition marks Bitcoin Depot’s first entry into the P2P social betting market and reflects the Company’s broader strategy to diversify its product offerings beyond its core Bitcoin ATM business. Kutt’s platform is positioned within one of the fastest-growing segments of consumer fintech, as Americans wagered over $165 billion through U.S. sportsbooks in 2025, reflecting the continued expansion...

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J Code Permanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient access JELMYTO® achieved net product sales of $94 million in 2025, representing year-over-year underlying demand sales growth of 7% Announced refinancing of existing term loan with Pharmakon Advisors that provides additional non-dilutive capital at more favorable terms Conference call and webcast to be held today at 10:00 AM ETPRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd....

Uniti Group Inc. Reports Fourth Quarter and Full Year 2025 Results

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Recently Completed Inaugural Kinetic ABS and Refinancing Activity Strengthens Uniti’s Balance Sheet at Attractive Cost of Capital Signed Largest Customer Contract in Uniti’s History with Prominent Hyperscaler Provides Full Year 2026 OutlookNet Loss of $305.7 Million for the Fourth Quarter and Net Income of $1,304.7 Million for the Full Year Consolidated Revenue and Adjusted EBITDA of $917.3 Million and $365.6 Million, Respectively, for the Fourth Quarter Consolidated Revenue and Adjusted EBITDA of $2,234.5 Million and $1,173.8 Million, Respectively, for the Full YearLITTLE ROCK, Ark., March 02, 2026 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the fourth quarter and full year 2025. Key highlights during the quarter on a pro forma basis included:Consolidated...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals